Barnett & Company’s Biogen BIIB Stock Holding History

Barnett & Company’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-8	Closed	-$2K	–	452
2019 Q3	$2K	Buy	+8	New	+$1.86K	﹤0.01%	307

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Barnett & Company's BIIB Position: Q4 2019 in Review

Barnett & Company sold out of Biogen (BIIB) in Q4 2019, closing a stake of 8 shares — an estimated $2K sold.

Barnett & Company first reported a position in BIIB in Q3 2019 and held it in 1 quarter. The position peaked at $2K in Q3 2019. 1,103 funds tracked by Wall St. Rank hold BIIB as of Q4 2019.

Barnett & Company reported no remaining Biogen position as of Q4 2019 after selling out during the quarter.
Barnett & Company sold 8 Biogen shares in Q4 2019, an estimated $2K.
Barnett & Company first reported a position in Biogen in Q3 2019 and held it in 1 quarter.
Barnett & Company's Biogen position peaked at $2K in Q3 2019.
1,103 funds tracked by Wall St. Rank held Biogen as of Q4 2019.

Based on Barnett & Company's 13F filing for Q4 2019, filed 22 Jan 2020.